Thromboxane b2

Thromboxane b2 is a lipid of Fatty Acyls (FA) class. Thromboxane b2 is associated with abnormalities such as endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia and Thrombocytosis. The involved functions are known as Platelet Activation, Excretory function, Anabolism, Inflammation and mRNA Expression. Thromboxane b2 often locates in Endothelium, Hepatic and Microsomes, Liver. The associated genes with Thromboxane b2 are PTGS2 gene, prothrombin fragment 2 and CCL14 wt Allele.

Cross Reference

Introduction

To understand associated biological information of Thromboxane b2, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Thromboxane b2?

Thromboxane b2 is suspected in endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia, Thrombocytosis, Acute Coronary Syndrome and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Thromboxane b2

MeSH term MeSH ID Detail
Diabetes Mellitus, Experimental D003921 85 associated lipids
Mammary Neoplasms, Experimental D008325 67 associated lipids
Body Weight D001835 333 associated lipids
Edema D004487 152 associated lipids
Arthritis D001168 41 associated lipids
Arthritis, Experimental D001169 24 associated lipids
Hypotension D007022 41 associated lipids
Acute Kidney Injury D058186 34 associated lipids
Gastritis D005756 27 associated lipids
Heart Failure D006333 36 associated lipids
Per page 10 20 50 100 | Total 293

PubChem Associated disorders and diseases

What pathways are associated with Thromboxane b2

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Thromboxane b2?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Thromboxane b2?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Thromboxane b2?

There are no associated biomedical information in the current reference collection.

What genes are associated with Thromboxane b2?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Thromboxane b2?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with Thromboxane b2

Download all related citations
Per page 10 20 50 100 | Total 6367
Authors Title Published Journal PubMed Link
Olson MT et al. Effect of assay specificity on the association of urine 11-dehydro thromboxane B2 determination with cardiovascular risk. 2012 J. Thromb. Haemost. pmid:23072449
Chen CY et al. Functional analysis of human thromboxane synthase polymorphic variants. 2012 Pharmacogenet. Genomics pmid:22735388
Alizzi AM et al. Reduction of post-surgical pericardial adhesions using a pig model. 2012 Heart Lung Circ pmid:22078313
Hui C et al. Changes in coagulation and hemodynamics during pregnancy: a prospective longitudinal study of 58 cases. 2012 Arch. Gynecol. Obstet. pmid:22083312
Hu YY et al. Six alkaloids inhibit secretion of IL-1α, TXB(2), ET-1 and E-selectin in LPS-induced endothelial cells. 2012 Immunol. Invest. pmid:22087636
Shoeb M and Ramana KV Anti-inflammatory effects of benfotiamine are mediated through the regulation of the arachidonic acid pathway in macrophages. 2012 Free Radic. Biol. Med. pmid:22067901
Pelligand L et al. Pharmacokinetic/pharmacodynamic modelling of robenacoxib in a feline tissue cage model of inflammation. 2012 J. Vet. Pharmacol. Ther. pmid:21767277
Wenzel F et al. Determination of thromboxane formation, soluble CD40L release and thrombopoietin clearance in apheresis platelet concentrates. 2012 Platelets pmid:21806498
Tong Z et al. Influence of ShuJinHuoXue tablets on ischemia reperfusion injury of animals' skeletal muscle. 2012 Molecules pmid:22801363
Cesari M et al. Oxidative damage, platelet activation, and inflammation to predict mobility disability and mortality in older persons: results from the health aging and body composition study. 2012 J. Gerontol. A Biol. Sci. Med. Sci. pmid:22389462
Dragani A et al. Oxidative stress and platelet activation in subjects with moderate hyperhomocysteinaemia due to MTHFR 677 C→T polymorphism. 2012 Thromb. Haemost. pmid:22782530
Saito Y et al. Disruption of group IVA cytosolic phospholipase A(2) attenuates myocardial ischemia-reperfusion injury partly through inhibition of TNF-α-mediated pathway. 2012 Am. J. Physiol. Heart Circ. Physiol. pmid:22427514
Wang Z et al. Aspirin resistance in off-pump coronary artery bypass grafting. 2012 Eur J Cardiothorac Surg pmid:21636287
Skarke C et al. Comparative impact on prostanoid biosynthesis of celecoxib and the novel nonsteroidal anti-inflammatory drug CG100649. 2012 Clin. Pharmacol. Ther. pmid:22278334
Li C et al. Reversal of the anti-platelet effects of aspirin and clopidogrel. 2012 J. Thromb. Haemost. pmid:22268852
Rodríguez-Vilarrupla A et al. PPARα activation improves endothelial dysfunction and reduces fibrosis and portal pressure in cirrhotic rats. 2012 J. Hepatol. pmid:22245887
Mullins KB et al. Effects of carprofen, meloxicam and deracoxib on platelet function in dogs. 2012 Vet Anaesth Analg pmid:22248445
Bednar F et al. Evaluation of aspirin's effect on platelet function early after coronary artery bypass grafting. 2012 J. Cardiothorac. Vasc. Anesth. pmid:22281116
Cathcart CJ et al. Lack of inhibitory effect of acetylsalicylic acid and meloxicam on whole blood platelet aggregation in cats. 2012 J Vet Emerg Crit Care (San Antonio) pmid:22316324
Mo J et al. Expression of interleukin-18 in a rat model of deep vein thrombosis. 2012 J Cardiovasc Surg (Torino) pmid:22318348
Hartanto MD et al. Urinary 11-dehydro-thromboxane B₂ and 2,3-dinor-6-keto-prostaglandin-F₁α in healthy post-menopausal and pre-menopausal women receiving aspirin 100 mg. 2012 J. Thromb. Thrombolysis pmid:22311294
Smith JP et al. Suboptimal inhibition of platelet cyclooxygenase-1 by aspirin in metabolic syndrome. 2012 Hypertension pmid:22311905
Brivio I et al. The pulmonary pharmacology of [4-methoxy-N1-(4-trans-nitrooxycyclohexyl)-N3-(3-pyridinylmethyl)-1,3-benzenedicarboxamide] (2NTX-99), an anti-atherotrombotic compound with therapeutic potential in pathological conditions that target lung vasculature. 2012 Prostaglandins Other Lipid Mediat. pmid:22342851
Lemkes BA et al. The influence of aspirin dose and glycemic control on platelet inhibition in patients with type 2 diabetes mellitus. 2012 J. Thromb. Haemost. pmid:22252020
Matsuzawa S et al. Ibudilast, a phosphodiesterase inhibitor, in combination with low-dose aspirin potently inhibits guinea pig carotid artery thrombosis without extending bleeding time and causing gastric mucosal injury. 2012 Arzneimittelforschung pmid:22945770
Chen C et al. [Effects of extracts of Radix Scrophulariae on blood pressure in spontaneously hypertensive rats and the underlying mechanisms]. 2012 Zhong Xi Yi Jie He Xue Bao pmid:22979933
Shatoor AS et al. Effect of Hawthorn (Crataegus aronia syn. Azarolus (L)) on platelet function in albino Wistar rats. 2012 Thromb. Res. pmid:22261477
Brentnall C et al. Potency and selectivity of carprofen enantiomers for inhibition of bovine cyclooxygenase in whole blood assays. 2012 Res. Vet. Sci. pmid:22703724
Peters SM et al. In vivo characterization of inflammatory biomarkers in swine and the impact of flunixin meglumine administration. 2012 Vet. Immunol. Immunopathol. pmid:22648045
Zhou MT et al. Continuous regional arterial infusion with fluorouracil and octreotide attenuates severe acute pancreatitis in a canine model. 2012 PLoS ONE pmid:22655040
Saadawi S et al. Inhibitory effects of acetylmelodorinol, chrysin and polycarpol from Mitrella kentii on prostaglandin Eâ‚‚ and Thromboxane Bâ‚‚ production and platelet activating factor receptor binding. 2012 Molecules pmid:22538486
Sadilkova L et al. The purification step is not crucial in EIA measurements of thromboxane B2 and 11-dehydrothromboxane B2 in human plasma. 2012 Clin. Lab. pmid:22372363
Ju HK et al. Metabolomic investigation of the anti-platelet aggregation activity of ginsenoside Rk₁ reveals attenuated 12-HETE production. 2012 J. Proteome Res. pmid:22873173
Matsuura E et al. On aspirin treatment but not baseline thromboxane B2 levels predict adverse outcomes in patients with acute coronary syndromes. 2012 J. Thromb. Haemost. pmid:22784188
Chandrasekaran CV et al. In vitro comparative evaluation of non-leaves and leaves extracts of Andrographis paniculata on modulation of inflammatory mediators. 2012 Antiinflamm Antiallergy Agents Med Chem pmid:22882083
Yokoyama H et al. Theoretical investigation of aspirin dosage regimen to exhibit optimal antiplatelet effects and decrease risk of upper gastrointestinal lesions. 2012 Biol. Pharm. Bull. pmid:23047244
Liou JT et al. Levobupivacaine differentially suppresses platelet aggregation by modulating calcium release in a dose-dependent manner. 2012 Acta Anaesthesiol Taiwan pmid:23026170
Thomason J et al. Platelet cyclooxygenase expression in normal dogs. 2011 Sep-Oct J. Vet. Intern. Med. pmid:21985141
Alcott CJ et al. Clinical and immunomodulating effects of ketamine in horses with experimental endotoxemia. 2011 Jul-Aug J. Vet. Intern. Med. pmid:21745244
Chakroun T et al. The cyclooxygenase-1 C50T polymorphism is not associated with aspirin responsiveness status in stable coronary artery disease in Tunisian patients. 2011 Jul-Aug Genet Test Mol Biomarkers pmid:21434767
Saihkay HN et al. Validating 123I-metaiodobenzylguanidine as a platelet marker for non-invasive imaging in rabbits. 2011 Jan-Feb J Pharmacol Toxicol Methods pmid:20646985
Brainard BM et al. Effects of clopidogrel and aspirin on platelet aggregation, thromboxane production, and serotonin secretion in horses. 2011 Jan-Feb J. Vet. Intern. Med. pmid:21143302
Mattiello T et al. Aspirin extrusion from human platelets through multidrug resistance protein-4-mediated transport: evidence of a reduced drug action in patients after coronary artery bypass grafting. 2011 J. Am. Coll. Cardiol. pmid:21816313
Ramadan E et al. Chronic valproate treatment blocks D2-like receptor-mediated brain signaling via arachidonic acid in rats. 2011 Neuropharmacology pmid:21839100
Lomakin NV and Gruzdev AK [Cyclooxygenase inhibitors and antiplatelet effect of acetylsalicylic acid. selective approach to nonsteroidal anti-inflammatory drugs in cardiological practice]. 2011 Kardiologiia pmid:21878085
Basselin M et al. Anti-inflammatory effects of chronic aspirin on brain arachidonic acid metabolites. 2011 Neurochem. Res. pmid:20981485
Oates JC et al. Selective cyclooxygenase-2 inhibitor suppresses renal thromboxane production but not proliferative lesions in the MRL/lpr murine model of lupus nephritis. 2011 Am. J. Med. Sci. pmid:20924284
Grove EL et al. Effect of platelet turnover on whole blood platelet aggregation in patients with coronary artery disease. 2011 J. Thromb. Haemost. pmid:20955349
Basselin M et al. Imaging upregulated brain arachidonic acid metabolism in HIV-1 transgenic rats. 2011 J. Cereb. Blood Flow Metab. pmid:20664612
Lordkipanidzé M et al. Heterogeneity in platelet cyclooxygenase inhibition by aspirin in coronary artery disease. 2011 Int. J. Cardiol. pmid:20207433